Global Biobank Meta-analysis Initiative: powering genetic discovery across human diseases

Wei Zhou, Masahiro Kanai, Kuan-Han Wu, Humaira Rasheed, Kristin Tsuo, Jibril Hirbo, Ying Wang, Arjun Bhattacharya, Huiling Zhao, Shinichi Namba, Ida Surakka, Brooke N. Wolford, Valeria Lo Faro, Esteban A. Lopera-Maya, Kristi Läll, Marie-Julie Favé, Sinéad B. Chapman, Juha Karjalainen, Mitja Kurki, Mutaamba Maasha, Ben Brumpton, Sameer Chavan, Tzu‐Ting Chen, Michelle Daya, Yi Ding, Yen‐Chen Anne Feng, Christopher R. Gignoux, Sarah E. Graham, Whitney Hornsby, Nathan Ingold, Ruth Johnson, Triin Laisk, Kuang Lin, Jun Lv, Iona Y. Millwood, Priit Palta, Anita Pandit, Michael Preuß, Unnur Þorsteinsdóttir, Jasmina Uzunović, Matthew Zawistowski, Xue Zhong, Archie Campbell, Kristy Crooks, Geertruida H. de Bock, Nicholas J. Douville, Sarah Finer, Lars G. Fritsche, Chris Griffiths, Yu Guo, Karen A. Hunt, Takahiro Konuma, Riccardo E. Marioni, Jansonius Nomdo, Snehal Patil, Nicholas Rafaels, Anne Richmond, Jonathan Shortt, Péter Straub, Ran Tao, Brett Vanderwerff, Kathleen C. Barnes, Marike Boezen, Zhengming Chen, Chia‐Yen Chen, Judy H. Cho, George Davey Smith, Hilary K. Finucane, Lude Franke, Eric R. Gamazon, Andrea Ganna, Tom R. Gaunt, Tian Ge, Hailiang Huang, Jennifer E. Huffman, Clara Lajonchere, Matthew H. Law, Liming Li, Cecilia M. Lindgren, Ruth J. F. Loos, Stuart MacGregor, Koichi Matsuda, Catherine M. Olsen, David J. Porteous, Jordan A. Shavit, Harold Snieder, Richard C. Trembath, Judith M. Vonk, David C. Whiteman, Stephen J. Wicks, Cisca Wijmenga, John Wright, Jie Zheng, Xiang Zhou, Philip Awadalla, Michael Boehnke, Nancy J. Cox, Daniel H. Geschwind, Caroline Hayward, Kristian HveemmedRxiv 2021 · DOI

Abstract

Biobanks are being established worldwide to understand the genetic and environmental foundations of human disease. While genome-wide association studies (GWAS) have successfully mapped thousands of genomic loci, they often lack representation of diverse ancestries. The Global Biobank Meta-analysis Initiative (GBMI) addresses this by creating a collaborative network of 19 biobanks across four continents, representing over 2.1 million individuals. By harmonizing genotypes and phenotypes across six major ancestry groups, GBMI meta-analyzed 14 exemplar diseases. This effort demonstrates that global biobank data can be successfully integrated despite inherent heterogeneity, significantly improving GWAS power, increasing ancestral representation, and enhancing risk prediction for understudied diseases and populations.

Introduction: Addressing the Diversity Crisis in Genetics

For over 15 years, Genome-Wide Association Studies (GWAS) have been the cornerstone of medical genetics. However, the field faces a significant "diversity crisis," as the vast majority of studies rely on individuals of European ancestry. This bias limits our ability to discover genetic variants that may be more prevalent or have different effects in other populations, hindering the progress of global precision medicine.

Furthermore, global biobanks often operate in silos, utilizing varied recruitment strategies and disease classification systems. The Global Biobank Meta-analysis Initiative (GBMI) was established to overcome these barriers by creating a unified framework to harmonize disparate datasets, enabling meta-analysis of a massive, multi-ancestry global cohort.

Methods: A Standardized Pipeline for Global Integration

The GBMI developed a robust pipeline to integrate data from 19 biobanks across four continents. The methodology focused on several key areas:

  • Phenotype Harmonization: Researchers mapped diverse International Classification of Diseases (ICD) codes to "phecodes"—standardized groupings of related symptoms and diagnoses—to ensure consistency across different healthcare systems.
  • Ancestry Projection: Using Principal Component Analysis (PCA), participants were projected into a shared genetic space based on reference datasets (1000 Genomes and HGDP). This ensured consistent ancestry labeling across six major groups: African (AFR), Admixed American (AMR), Central and South Asian (CSA), East Asian (EAS), European (EUR), and Middle Eastern (MID).
  • Meta-Analysis Techniques: The study employed standard inverse-variance weighting alongside MR-MEGA, a meta-regression technique specifically designed to manage the heterogeneity inherent in multi-ancestry data.
  • In Silico Prioritization: To identify likely causal genes from statistical associations, the team integrated functional genomics tools, including DEPICT, PoPS, and transcriptome-wide association studies (TWAS).

Data and Ancestry: A Global Resource

The initiative leverages data from 2.1 million consented individuals across 19 biobanks, including the UK Biobank, FinnGen, Biobank Japan, and several US-based systems like BioVU.

Global distribution and composition of the 19 participating biobanks.

While the cohort remains majority European (1.4M), it includes substantial representation from East Asian (341k), African (33k), Central/South Asian (31k), and Admixed American (18k) populations. The study focused on 14 exemplar conditions, ranging from common diseases like asthma and stroke to understudied conditions like idiopathic pulmonary fibrosis and gout.

Results: Discovery Through Diversity

The GBMI's collaborative approach yielded significant insights into the genetic architecture of human disease:

  • Novel Loci Discovery: The meta-analysis identified 508 total loci reaching genome-wide significance, including 188 novel loci never previously reported. By including non-European samples, the team analyzed 21.8 million genetic variants absent from standard European reference sets, leading to 165 discoveries that would have otherwise been missed.
  • Cross-Biobank Consistency: Approximately 96% of identified genetic effects were consistent across different biobanks, suggesting that underlying genetic signals are remarkably robust despite variations in recruitment and disease definition.
  • Power and Prediction: For asthma, the initiative identified 180 loci (49 novel), nearly tripling the discovery power of previous studies. Polygenic Risk Scores (PRS) derived from this multi-ancestry data significantly outperformed previous models, particularly for non-European individuals.
Summary of discovered loci and effective sample sizes across 14 diseases (A) and effect sizes vs risk allele frequency (B).

Discussion and Future Directions

While the GBMI marks a significant step forward, challenges remain. The "representation gap" persists, as many African and Admixed American samples were sourced from US-based biobanks rather than their regions of origin. Additionally, discordance between different "in silico" gene prioritization methods highlights a bottleneck in moving from genetic hits to biological understanding.

Future work will focus on deeper integration of proteomic and transcriptomic data to bridge the gap between genetic associations and druggable targets, further advancing the goal of equitable global precision medicine.

Summary updated

Abstract

Summary Biobanks are being established across the world to understand the genetic, environmental, and epidemiological basis of human diseases with the goal of better prevention and treatments. Genome-wide association studies (GWAS) have been very successful at mapping genomic loci for a wide range of human diseases and traits, but in general, lack appropriate representation of diverse ancestries - with most biobanks and preceding GWAS studies composed of individuals of European ancestries. Here, we introduce the Global Biobank Meta-analysis Initiative (GBMI) -- a collaborative network of 19 biobanks from 4 continents representing more than 2.1 million consented individuals with genetic data linked to electronic health records. GBMI meta-analyzes summary statistics from GWAS generated using harmonized genotypes and phenotypes from member biobanks. GBMI brings together results from GWAS analysis across 6 main ancestry groups: approximately 33,000 of African ancestry either from Africa or from admixed-ancestry diaspora (AFR), 18,000 admixed American (AMR), 31,000 Central and South Asian (CSA), 341,000 East Asian (EAS), 1.4 million European (EUR), and 1,600 Middle Eastern (MID) individuals. In this flagship project, we generated GWASs from across 14 exemplar diseases and endpoints, including both common and less prevalent diseases that were previously understudied. Using the genetic association results, we validate that GWASs conducted in biobanks worldwide can be successfully integrated despite heterogeneity in case definitions, recruitment strategies, and baseline characteristics between biobanks. We demonstrate the value of this collaborative effort to improve GWAS power for diseases, increase representation, benefit understudied diseases, and improve risk prediction while also enabling the nomination of disease genes and drug candidates by incorporating gene and protein expression data and providing insight into the underlying biology of the studied traits.
BibTeX
@misc{zhou2021global,
  author = {Wei Zhou and Masahiro Kanai and Kuan-Han Wu and Humaira Rasheed and Kristin Tsuo and Jibril Hirbo and Ying Wang and Arjun Bhattacharya and Huiling Zhao and Shinichi Namba and Ida Surakka and Brooke N. Wolford and Valeria Lo Faro and Esteban A. Lopera-Maya and Kristi Läll and Marie-Julie Favé and Sinéad B. Chapman and Juha Karjalainen and Mitja Kurki and Mutaamba Maasha and Ben Brumpton and Sameer Chavan and Tzu‐Ting Chen and Michelle Daya and Yi Ding and Yen‐Chen Anne Feng and Christopher R. Gignoux and Sarah E. Graham and Whitney Hornsby and Nathan Ingold and Ruth Johnson and Triin Laisk and Kuang Lin and Jun Lv and Iona Y. Millwood and Priit Palta and Anita Pandit and Michael Preuß and Unnur Þorsteinsdóttir and Jasmina Uzunović and Matthew Zawistowski and Xue Zhong and Archie Campbell and Kristy Crooks and Geertruida H. de Bock and Nicholas J. Douville and Sarah Finer and Lars G. Fritsche and Chris Griffiths and Yu Guo and Karen A. Hunt and Takahiro Konuma and Riccardo E. Marioni and Jansonius Nomdo and Snehal Patil and Nicholas Rafaels and Anne Richmond and Jonathan Shortt and Péter Straub and Ran Tao and Brett Vanderwerff and Kathleen C. Barnes and Marike Boezen and Zhengming Chen and Chia‐Yen Chen and Judy H. Cho and George Davey Smith and Hilary K. Finucane and Lude Franke and Eric R. Gamazon and Andrea Ganna and Tom R. Gaunt and Tian Ge and Hailiang Huang and Jennifer E. Huffman and Clara Lajonchere and Matthew H. Law and Liming Li and Cecilia M. Lindgren and Ruth J. F. Loos and Stuart MacGregor and Koichi Matsuda and Catherine M. Olsen and David J. Porteous and Jordan A. Shavit and Harold Snieder and Richard C. Trembath and Judith M. Vonk and David C. Whiteman and Stephen J. Wicks and Cisca Wijmenga and John Wright and Jie Zheng and Xiang Zhou and Philip Awadalla and Michael Boehnke and Nancy J. Cox and Daniel H. Geschwind and Caroline Hayward and Kristian Hveem},
  title = {{Global Biobank Meta-analysis Initiative: powering genetic discovery across human diseases}},
  year = {2021},
  doi = {10.1101/2021.11.19.21266436},
  howpublished = {medRxiv},
}
Figure